Who
Brian F. Sullivan
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Celcuity; Director, Entegris; Director, Virtual Radiologic; Director, Sontra Medical.
In numbers
- Trades disclosed
- 156
- Buys
- 3
- Sells
- 14
- Bought
- $1.9M
- Sold
- $3.1M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 23 May 2006
- Last trade
- 14 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Aug 2026filed 18 Aug 2026 | CELC CelcuityBiotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 14 Aug 2026filed 18 Aug 2026 | CELC Celcuityoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 14 Aug 2026filed 18 Aug 2026 | CELC Celcuityoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 14 Aug 2026filed 18 Aug 2026 | CELC CelcuityBiotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 2 Sep 2025filed 4 Sep 2025 | CELC Celcuityoption or derivative · Biotechnology | SEC FORM 4 Code X | —104,340 at $0.00 | filing |
| 2 Sep 2025filed 4 Sep 2025 | CELC CelcuityBiotechnology | SEC FORM 4 Code X | $840K104,340 at $8.05 | filing |
| 18 Aug 2025filed 20 Aug 2025 | CELC Celcuityoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 18 Aug 2025filed 20 Aug 2025 | CELC Celcuityoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 14 Apr 2025filed 15 Apr 2025 | CELC CelcuityBiotechnology | SEC FORM 4 Code G | —8,155 at $0.00 | filing |
| 14 Apr 2025filed 15 Apr 2025 | CELC CelcuityBiotechnology | SEC FORM 4 Code G | —8,155 at $0.00 | filing |
| 4 Mar 2025filed 5 Mar 2025 | CELC CelcuityBiotechnology | SEC FORM 4 Code G | —36,845 at $0.00 | filing |
| 4 Mar 2025filed 5 Mar 2025 | CELC CelcuityBiotechnology | SEC FORM 4 Code G | —36,845 at $0.00 | filing |
| 3 Mar 2025filed 5 Mar 2025 | CELC CelcuityBiotechnology | SEC FORM 4 Code G | —39,670 at $0.00 | filing |
| 3 Mar 2025filed 5 Mar 2025 | CELC CelcuityBiotechnology | SEC FORM 4 Code G | —39,670 at $0.00 | filing |
| 3 Mar 2025filed 5 Mar 2025 | CELC CelcuityBiotechnology | SEC FORM 4 Code G | —45,000 at $0.00 | filing |
| 3 Mar 2025filed 5 Mar 2025 | CELC CelcuityBiotechnology | SEC FORM 4 Code G | —45,000 at $0.00 | filing |
| 20 Aug 2024filed 22 Aug 2024 | CELC Celcuityoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 20 Aug 2024filed 22 Aug 2024 | CELC Celcuityoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 20 Aug 2024filed 22 Aug 2024 | CELC CelcuityBiotechnology | SEC FORM 4 Code G | —189,103 at $0.00 | filing |
| 20 Aug 2024filed 22 Aug 2024 | CELC CelcuityBiotechnology | SEC FORM 4 Code G | —189,103 at $0.00 | filing |
News
Entegris, Inc. (NASDAQ:ENTG) Shares Will Pay Quarterly Dividend of $0.10ENTG · dailypolitical.com · 14 Oct 2026Truist Financial Begins Coverage on Entegris (NASDAQ:ENTG)ENTG · dailypolitical.com · 14 Oct 2026
0 headlines in the last 90 days name Brian F. Sullivan; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.